- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05452720
MASA Valve Early Feasibility Study (MVEFS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The MASA Valve is a bi-leaflet pulmonary valved conduit. The MASA Valve has an ePTFE conduit and ePTFE leaflets fixtured to the conduit with polypropylene suture. The device has a pad-printed design on the outer conduit surface indicating the valve position and direction of flow. .
The MASA Valve is intended to be used to reconstruction the Right Ventricular Outflow Tract (RVOT) and provide a functional pulmonary valve. Once implanted, the MASA Valve provides a pathway for blood from the Right Ventricle (RV) to the Pulmonary Arteries (PAs), while the integrated valve helps to prevent backflow into the RV. The MASA Valve Indications for Use are:
The MASA Valve pulmonary valved conduit is indicated for correction or reconstruction of the right ventricular outflow tract (RVOT) in patients aged less than 22 years with any of the following congenital cardiac malformations:
- Pulmonary Stenosis
- Tetralogy of Fallot
- Truncus Arteriosus
- Transposition of Great Vessels
- Pulmonary Atresia
In addition, the MASA Valve is indicated for the replacement of previously implanted, but dysfunctional, pulmonary valves, valved conduits or conduits, as well as for use in the Ross Procedure when the native RVOT is being used to reconstruct the Aorta.
Treatments currently available for the above-stated conditions include biologic-tissue-based valved conduits (Homografts and Contegra Glutaraldehyde-fixed Bovine Jugular Vein), Intra-operatively constructed valved conduits made from off-the-shelf vascular grafts and cardiovascular membranes, and non-valved cardiovascular conduits. Based on existing evidence it is believed the potential benefits of MASA Valve outweigh the potential risks.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Arush Kalra, MBBS, MS
- Phone Number: 4123300746
- Email: arush@pecalabs.com
Study Contact Backup
- Name: Doug Bernstein, BS
- Phone Number: 4125899847
- Email: doug@pecalabs.com
Study Locations
-
-
Illinois
-
Peoria, Illinois, United States, 61637
- Recruiting
- OSF Childrens Hospital of Illinois
-
Contact:
- Drewann Whalen
- Phone Number: 217-714-6496
- Email: Drewann.S.Whalen@osfhealthcare.org
-
Principal Investigator:
- Harma Terbendian, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Boston Childrens Hospital
-
Contact:
- David Hoganson, MD
- Phone Number: 314-610-6063
- Email: David.Hoganson@cardio.chboston.org
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- NewYork-Presbyterian Morgan Stanley Children's Hospital
-
Contact:
- Shieca Cenado
- Phone Number: 646-726-5528
- Email: sc5035@cumc.columbia.edu
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Cincinnati Children's Hospital
-
Contact:
- Joshua Freytag
- Phone Number: 513-803-1910
- Email: Joshua.Freytag@cchmc.org
-
Principal Investigator:
- David Morales, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Childrens Hospital of Philadelphia
-
Contact:
- William Gaynor, MD
- Email: gaynor@chop.edu
-
-
Texas
-
Dallas, Texas, United States, 75235
- Recruiting
- Childrens Medical Center Dallas
-
Contact:
- Kara Lorduy
- Email: Kara.Lorduy@childrens.com
-
Principal Investigator:
- Karl Reyes, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- At least one of the following: Right Ventricular to Pulmonary Artery mean gradient > 35mm Hg, moderate or severe Pulmonary regurgitation (≥3+), or clinical indication for replacement of their native or prosthetic pulmonary valve with a prosthesis.
- Age < 22 years
- Patient is geographically stable and willing to return for 1 year follow-up for the trial.
- Patient's legal guardian should be willing to provide informed consent (IC) at the hospital location where they are being enrolled.
- The patient, and the patient's parent / legal representative where appropriate, and the treating physician agree that the subject will return for all required post-procedure follow up visits and the subject will comply with clinical investigation plan required follow-up visits.
Exclusion Criteria:
- Patient is in need of or has presence of a prosthetic heart valve at any other position
- Patient has a need for concomitant surgical procedures (non-cardiac)
- Patients with previously implanted pacemaker (including defibrillators) or mechanical valves
- Patient has an active bacterial or viral infection or requiring current antibiotic therapy (if temporary illness, patient may be a candidate 4 weeks after discontinuation of antibiotics)
- Patient has an active endocarditis
- Leukopenia, according to local laboratory evaluation of white blood cell count
- Acute or chronic anemia, according to local laboratory evaluation of hemoglobin Patients can be transfused to meet eligibility criteria
- Thrombocytopenia, defined as Platelet count < 150,000/mm3 Patients can be transfused to meet eligibility criteria
- Severe chest wall deformity, which would preclude placement of the PV conduit
- Known hypersensitivity to anticoagulants and antiplatelet drugs and to the device materials
- Immunocompromised patient defined as: autoimmune disease, patients receiving immunosuppressant drugs or immune stimulant drugs
- Patient has chronic inflammatory / autoimmune disease
- Need for emergency cardiac or vascular surgery or intervention
- Major or progressive non-cardiac disease (liver failure, renal failure, cancer) that has a life expectancy of less than one year
- Currently participating, or participated within the last 30 days, in an investigational drug or device study
- Alcohol or drug abuse as defined by DSM IV-TR criteria for substance abuse - this includes the illicit use of cannabis within the last 12 months
- Patient has medical, social or psychosocial factors that, in the opinion of the Investigator, could have impact on safety or compliance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental Arm
This is a single-arm study.
All participants in this study will undergo implantation with MASA Valve.
|
Surgical replacement of the Pulmonary Valve or a previously implanted prosthetic with the investigational device (MASA Valve)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from device related death
Time Frame: 1 year
|
Percentage of patients that have not died related to the device 1 year from implantation
|
1 year
|
Freedom from Explant
Time Frame: 1 year
|
Percentage of patients that have not undergone device explant within 1 year from implantation
|
1 year
|
Freedom from Device-Related Reoperation
Time Frame: 1 year
|
Percentage of patients that have not undergone re-operation related to the device within 1 year from implantation
|
1 year
|
Freedom from Device-Related Catheter Intervention
Time Frame: 1 year
|
Percentage of patients that have not undergone device related catheter based intervention within 1 year from implantation
|
1 year
|
Freedom from Endocarditis
Time Frame: 1 year
|
Percentage of patients that have not had endocarditis within 1 year from implantation
|
1 year
|
Freedom from Thrombus
Time Frame: 1 year
|
Percentage of patients that have not had a serious thrombotic event related to the device within 1 year from implantation
|
1 year
|
Freedom from Major Hemorrhage
Time Frame: 1 year
|
Percentage of patients that have not had a major bleeding episode related to the device within 1 year from implantation
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from Moderate or Greater Pulmonary Regurgitation
Time Frame: 1 year
|
Percentage of patients that show less than Moderate Pulmonary Regurgitation within 1 year from implantation on Echocardiographic assessment
|
1 year
|
Freedom from Pulmonary Gradient ≥36mmHg
Time Frame: 1 year
|
Percentage of patients that have a Pulmonary Gradient <= 36mmHg within 1 year from implantation on Echocardiographic assessment
|
1 year
|
Freedom from device valve failure
Time Frame: 1 year
|
Percentage of patients that show do not show valve functional failure on Echocardiographic assessment
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Morales, MD, Cinncinnati Childrens Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Congenital Abnormalities
- Heart Valve Diseases
- Ventricular Outflow Obstruction
- Heart Defects, Congenital
- Cardiovascular Abnormalities
- Vascular Malformations
- Heart Septal Defects
- Aortopulmonary Septal Defect
- Tetralogy of Fallot
- Pulmonary Valve Stenosis
- Transposition of Great Vessels
- Pulmonary Atresia
- Truncus Arteriosus, Persistent
Other Study ID Numbers
- G220040
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transposition of Great Vessels
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker Cochin; Imagine InstituteRecruiting
-
The Hospital for Sick ChildrenRecruitingTGA - Transposition of Great ArteriesCanada
-
Insel Gruppe AG, University Hospital BernSwiss National Science FoundationCompletedHeart Defects, Congenital | Transposition of Great Vessels With Ventricular InversionSwitzerland, Austria
-
Washington University School of MedicinePfizerTerminatedTetralogy of Fallot | Transposition of the Great Vessels With an Arterial Switch | Single Ventricle With a Fontan PalliationUnited States
-
University Hospital Inselspital, BerneCompletedTetralogy of Fallot | D-Transposition of Great ArteriesSwitzerland
-
Indiana UniversityCompletedTransposition of Great VesselsUnited States
-
Oslo University HospitalCompletedSurgery | Transposition of Great VesselsNorway
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceNot yet recruitingCongenital Heart Disease | Transposition of Great Vessels | Congenitally Corrected Transposition of the Great Arteries | Systemic Right Ventricle | Heart Failure CongenitalFrance
-
Boston Children's HospitalGeneral ElectricCompletedHypoplastic Left Heart Syndrome | Transposition of the Great Vessels | Oxygen Consumption Based Assessment of HemodynamicsUnited States
-
Children's Hospital of Fudan UniversityShanghai Children's Medical CenterCompletedTransposition of Great Vessels | Outcome, FatalChina
Clinical Trials on Surgical Right Ventricular Outflow Tract Reconstruction
-
Queen Fabiola Children's University HospitalCompletedCongenital Heart Defect | Right Ventricular Outflow Tract ReconstructionBelgium
-
Second Affiliated Hospital of Wenzhou Medical UniversityRecruitingVentricular Outflow Tract Ventricular Arrhythmias | Radio Frequency Catheter AblationChina
-
BioVentrixOhio State University; CDI Centro Diagnostico Italiano; Advance Research AssociatesCompletedHeart FailureItaly, Greece, Poland, Austria, Czechia, France, Latvia, Lithuania, Portugal, Spain, United Kingdom
-
BioVentrixOhio State University; Advance Research Associates; Centro Diagnostico ItalianoCompletedHeart FailureLatvia, Lithuania, Poland, Russian Federation
-
Fatebenefratelli HospitalFederico II University; Federal University of Rio Grande do Sul; Royal Brompton... and other collaboratorsRecruitingCoronary Artery Disease | Heart Failure | Aortic Valve Disease | Pulmonary Arterial Hypertension | Tetralogy of Fallot | Hypertrophic Cardiomyopathy | Athletes HeartItaly